Research
Hormonal
Chronic sleep restriction (4-5 hours/night) and total sleep deprivation cause insulin resistance and impaired glucose tolerance in healthy adults, mimicking Type 2 Diabetes pathophysiology.
Prioritize 7-8 hours of sleep nightly. Chronic restriction to 4-5 hours impairs insulin sensitivity and glucose tolerance, increasing Type 2 Diabetes risk. This is not just about feeling tired; it is a direct metabolic stressor.
GoodSupportsHIGH confidence
healthy human volunteers exposed to a rather severe paradigm of total sleep deprivation lasting from one to five days develop insulin resistance [73,74] and β-cell dysfunction [75]. ... partially sleep-deprived subjects also exhibited impairments in numerous parameters of glucose tolerance and insulin sensitivity [80-87]. Interestingly, the metabolic profile observed after sleep restriction shared several similarities with T2DM, including decreased muscle glucose uptake, increased liver glucose output and pancreatic β-cell dysfunction [80,83,84,88].
Why this rating
Supported by multiple experimental studies (total and partial sleep deprivation) and large-scale epidemiological data.
Source
The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms
Anne Briançon‐Marjollet et al. · Diabetology & Metabolic Syndrome · 2015
DOI 10.1186/s13098-015-0018-3
narrative_reviewCited 304×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obstructive Sleep Apnea (OSA) causes insulin resistance and Type 2 Diabetes through intermittent hypoxia, independent of obesity, via mechanisms involving sympathetic activation, oxidative stress, and inflammation.Good
- Circadian misalignment from shift work or forced desynchronization causes insulin resistance and impaired glucose tolerance, independent of total sleep time.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →